Francesca Colciaghi

Francesca Colciaghi

Auto-generated profile, based on publicly available information

Francesca Colciaghi

Epilepsy Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Neurologico Carlo Besta, Milan 20133, Italy

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
FCF. Colciaghi
F. Colciaghi
EMElena Marcello
Elena Marcello
BBB. Borroni
B. Borroni
MZM. Zimmermann
M. Zimmermann
CCC. Caltagirone
C. Caltagirone
MLM. Di Luca
M. Di Luca
Amyloid precursor protein (APP), ADAM 10, and β-site-APP cleaving enzyme (BACE) alterations were evaluated in platelets of 31 patients with Alzheimer disease (AD) and 15 age-matched controls. A significant modification of these proteins and enzymes involved in the amyloid cascade was detected from the earliest clinically detectable disease stage. This observation suggests that AD is associated with an early metabolic derangement toward amyloidogenic pathways and supports the potential value of APP and secretase measurements for early diagnosis of AD.

16 August 2004 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
MZMartina Zimmermann
Martina Zimmermann
FGFabrizio Gardoni
Fabrizio Gardoni
EMElena Marcello
Elena Marcello
FCFrancesca Colciaghi
Francesca Colciaghi
BBBarbara Borroni
Barbara Borroni
MLMonica Di Luca
Monica Di Luca

1 July 2004 in Neurobiology of Disease
Verified
Journal Article
Closed access
FCFrancesca Colciaghi
Francesca Colciaghi
BBBarbara Borroni
Barbara Borroni
MZMartina Zimmermann
Martina Zimmermann
CBCamilla Bellone
Camilla Bellone
ALAnnalisa Longhi
Annalisa Longhi
MLMonica Di Luca
Monica Di Luca

26 December 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
APA. Padovani
A. Padovani
LPL. Pastorino
L. Pastorino
BBB. Borroni
B. Borroni
FCF. Colciaghi
F. Colciaghi
LRL. Rozzini
L. Rozzini
MLM. Di Luca
M. Di Luca
Background: An altered pattern of amyloid precursor protein (APP) forms consisting in a reduced ratio between the upper (130 kDa) and the lower (106 to 110 kDa) immunoreactivity bands has been described in platelets of patients with AD. Objective: To evaluate the sensitivity and the specificity of platelet APP forms’ ratio (APPr) as a marker for AD. Methods: Eighty-five patients with probable AD and 95 control subjects (CON), including healthy individuals and neurologic patients, entered the study. Platelet APPr was evaluated by means of Western Blot analysis and immunostaining in the whole platelet homogenate, and calculated by the ratio between the optical density (OD) of the upper (130 kDa) and the lower (106 to 110 kDa) APP immunoreactive bands. Results: Mean APPr levels were decreased in AD patients (mean OD ± SD = 0.35 ± 0.18) compared with the CON group (mean OD ± SD = 0.92 ± 0.38) (DF 1, 178, p < 0.0001). Accuracy levels measured by Receiver Operating Curve analysis showed that a cut-off level of 0.57 resulted in a sensitivity of 88.2% and a specificity of 89.4%, with an area under the curve of 0.945. APPr levels were significantly associated with disease severity (mild AD versus moderate AD: p < 0.0001; moderate AD versus severe AD: p < 0.05). Conclusion: Platelet APPr allowed to differentiate AD from normal aging and other dementing disorders with high sensitivity and specificity. These findings suggest that platelet APPr may be of help as an adjunctive diagnostic tool in clinical practice.

1 January 2002 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
APAlessandro Padovani
Alessandro Padovani
BBBarbara Borroni
Barbara Borroni
FCFrancesca Colciaghi
Francesca Colciaghi
CPCarla Pettenati
Carla Pettenati
ECElisabetta Cottini
Elisabetta Cottini
MLMonica Di Luca
Monica Di Luca
ALZHEIMER DISEASE (AD) is a chronic neurodegenerative disorder characterized by a progressive cognitive and memory decline. It is defined by senile plaques, neurofibrillary tangles, and amyloid angiopathy, neuropathologic hallmarks that allow for a definitive diagnosis of the disease.1,2 In fact, pathologically confirmed preclinical AD occurs before the development of cognitive impairment,3 suggesting that AD lesions must be present for a sufficient length of time to produce neuronal or synaptic loss.4 On the other hand, there is evidence that in most cases the disease progresses to the stage of dementia after only several years from the appearance of the first behavioral symptoms.5-7

1 September 2000 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MLMonica Di Luca
Monica Di Luca
FCFrancesca Colciaghi
Francesca Colciaghi
LPLucia Pastorino
Lucia Pastorino
BBBarbara Borroni
Barbara Borroni
APAlessandro Padovani
Alessandro Padovani
FCFlaminio Cattabeni
Flaminio Cattabeni